We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00034983
First Posted: May 3, 2002
Last Update Posted: April 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
May 2, 2002
May 3, 2002
April 26, 2017
October 29, 2001
December 29, 2003   (Final data collection date for primary outcome measure)
Long-term safety and tolerability. [ Time Frame: Duration of treatment ]
Not Provided
Complete list of historical versions of study NCT00034983 on ClinicalTrials.gov Archive Site
Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences [ Time Frame: Duration of treatment ]
Not Provided
Not Provided
Not Provided
 
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
The duration of treatment is 1 year.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: aprepitant
    Other Name: MK0869
  • Drug: Comparator: paroxetine HCL
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
900
December 29, 2003
December 29, 2003   (Final data collection date for primary outcome measure)
Major Depressive Disorder
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00034983
0869-066
Formally-497B
MK0869-066
2006_407
Not Provided
Not Provided
Plan to Share IPD: Yes
Plan Description:

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php

Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP